A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression

[21] McShane LM(2003)Potential clinical utility of serum HER2/neu oncoprotein concentrations in patients with breast cancer Clin Chem 49 1579-1515

[22] Sauerbrei W(2006)Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer Clin Chem 52 1510-4110

[23] Lennon S(2012)Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer Chin Med J 125 4104-174

[24] Barton C(2002)New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 161-890

[25] Banken L(2008)Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival Ann Oncol 19 883-658

[26] Leary AF(1994)Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer Cancer 73 652-284

[27] Hanna WM(2012)High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients J Cancer Res Clin Oncol 138 275-879

[28] van de Vijver MJ(1997)Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro Int J Cancer 73 875-5129

[29] Molina R(1998)NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer Cancer Res 58 5123-1130

[30] Jo J(2004)Monitoring of serum HER2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer Anticancer Res 24 1127-501

[21] McShane LM(2003)Potential clinical utility of serum HER2/neu oncoprotein concentrations in patients with breast cancer Clin Chem 49 1579-1515

[22] Sauerbrei W(2006)Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer Clin Chem 52 1510-4110

[23] Lennon S(2012)Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer Chin Med J 125 4104-174

[24] Barton C(2002)New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 161-890

[25] Banken L(2008)Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival Ann Oncol 19 883-658

[26] Leary AF(1994)Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer Cancer 73 652-284

[27] Hanna WM(2012)High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients J Cancer Res Clin Oncol 138 275-879

[28] van de Vijver MJ(1997)Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro Int J Cancer 73 875-5129

[29] Molina R(1998)NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer Cancer Res 58 5123-1130

[30] Jo J(2004)Monitoring of serum HER2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer Anticancer Res 24 1127-501